SlideShare a Scribd company logo
Data-analytic sins in property-based
molecular design
Peter Kenny
pwk.pub.2008@gmail.com | http://fbdd-lit.blogspot.com
TEP =
[𝐷𝑟𝑢𝑔 𝑿,𝑡 ] 𝑓𝑟𝑒𝑒
𝐾 𝑑
Target engagement potential (TEP)
A basis for molecular design?
Property-based design as search for ‘sweet spot’
Correlation
• Strong correlation implies good predictivity
– I have observed a correlation so you must use my rule
• Multivariate data analysis (e.g. PCA) usually involves
transformation to orthogonal basis
• Applying cutoffs (e.g. MW restriction) to data can
distort correlations
• Noise and range limits in data
Quantifying strengths of relationships between
continuous variables
• Correlation measures
– Pearson product-moment correlation coefficient (R)
– Spearman's rank correlation coefficient ()
– Kendall rank correlation coefficient (τ)
• Quality of fit measures
– Coefficient of determination (R2) is the fraction of the
variance in Y that is explained by model
– Root mean square error (RMSE)
Preparation of synthetic data sets
Kenny & Montanari (2013) JCAMD 27:1-13 DOI
Add Gaussian noise
(SD=10) to Y
Correlation inflation by hiding variation
See Hopkins, Mason & Overington (2006) Curr Opin Struct Biol 16:127-136 DOI
Leeson & Springthorpe (2007) NRDD 6:881-890 DOI
Data is naturally binned (X is an integer) and mean value of Y is calculated for each
value of X. In some studies, averaged data is only presented graphically and it is left to
the reader to judge the strength of the correlation.
R = 0.34 R = 0.30 R = 0.31
R = 0.67 R = 0.93 R = 0.996
r
N 1202
R 0.247 ( 95% CI: 0.193 | 0.299)
 0.215 ( P < 0.0001)
 0.148 ( P < 0.0001)
N 8
R 0.972 ( 95% CI: 0.846 | 0.995)
 0.970 ( P < 0.0001)
 0.909 ( P = 0.0018)
Correlation Inflation in Flatland
See Lovering, Bikker & Humblet (2009) JMC 52:6752-6756 DOI
Masking variation with standard error
See Gleeson (2008) JMC 51:817-834 DOI
Partition by value of X into 4 bins with equal numbers of data points and display 95%
confidence interval for mean (green) and mean ± SD (blue) for each bin.
R = 0.12 R = 0.29 R = 0.28
N Bins Degrees of Freedom F P
40 4 3 0.2596 0.8540
400 4 3 12.855 < 0.0001
4000 4 3 115.35 < 0.0001
4000 2 1 270.91 < 0.0001
4000 8 7 50.075 < 0.0001
“In each plot provided, the width of the errors bars and the difference in the mean
values of the different categories are indicative of the strength of the relationship
between the parameters.” Gleeson (2008) JMC 51:817-834 DOI
The error of standard error
ANOVA for binned data sets
Know your data
• Assays are typically run in replicate making it possible
to estimate assay variance
• Every assay has a finite dynamic range and it may not
always be obvious what this is for a particular assay
• Dynamic range may have been sacrificed for
thoughput but this, by itself, does not make the
assay bad
• We need to be able analyse in-range and out-of-
range data within single unified framework
– See Lind (2010) QSAR analysis involving assay results which are only known to
be greater than, or less than some cut-off limit. Mol Inf 29:845-852 DOI
Depicting variation with
percentile plots
This graphical representation of data makes it easy
to visualize variation and can be used with mixed
in-range and out-of-range data. See Colclough et
al (2008) BMCL 16:6611-6616 DOI
Binning continuous data restricts your options for analysis and
places burden of proof on you to show that your conclusions are
independent of the binning scheme. Think before you bin!
Averaging the
binned data was
your idea so don’t
try blaming me this
time!
Correlation inflation: some stuff to think about
• Model continuous data as continuous data
– RMSE is most relevant to prediction but you still need R2
– Fitted parameters may provide insight (e.g. solubility is more sensitive than
potency to lipophilicity)
• When selecting training data think in terms of Design of Experiments
(e.g. evenly spaced values of X)
• Try to achieve normally distributed Y (e.g. use pIC50 rather than IC50)
• Never make statements about the strength of a relationship when
you’ve hidden or masked variation in the data (unless you want a
starring role in Correlation Inflation 2)
• To be meaningful, a measure of the spread of a distribution must be
independent of sample size
• Reviewers/editors, mercilessly purge manuscripts of statements like,
“A negative correlation was observed between X and Y” or “A and B are
correlated/linked”
Ligand efficiency metrics (LEMs) considered harmful
• We use LEMs to normalize activity with respect to risk
factors such as molecular size and lipophilicity
• What do we mean by normalization?
• We make assumptions about underlying relationship
between activity and risk factor(s) when we define an
LEM
• LEM as measure of extent to which activity beats a
trend?
Kenny, Leitão & Montanari (2014) JCAMD 28:699-710 DOI
Scale activity/affinity by risk factor
LE = ΔG/HA
Offset activity/affinity by risk factor
LipE = pIC50  ClogP
Ligand efficiency metrics
No reason that dependence of activity on risk factor should be restricted to
one of these two linear models
Use trend actually observed in data for normalization
rather than some arbitrarily assumed trend
There’s a reason why we say standard free energy
of binding…
DG = DH TDS = RTln(Kd/C0)
• Adoption of 1 M as standard concentration is
arbitrary
• A view of a chemical system that changes with
the choice of standard concentration is
thermodynamically invalid
NHA Kd/M C/M (1/NHA) log10(Kd/C)
10 10-3 1 0.30
20 10-6 1 0.30
30 10-9 1 0.30
10 10-3 0.1 0.20
20 10-6 0.1 0.25
30 10-9 0.1 0.27
10 10-3 10 0.40
20 10-6 10 0.35
30 10-9 10 0.33
Effect on LE of changing standard concentration
Scaling transformation of parallel lines by dividing Y by X
(This is how ligand efficiency is calculated)
Size dependency of LE is consequence of non-zero intercept
Affinity plotted against molecular weight for minimal binding
elements against various targets in inhibitor deconstruction
study showing variation in intercept term
Hajduk PJ (2006) J Med Chem 49:6972–6976 DOI
Is it valid to combine results from different assays in LE analysis?
Offsetting transformation of lines with different slope and
common intercept by subtracting X from Y
(This is how lipophilic efficiency is calculated)
Thankfully (hopefully?) nobody has ‘discovered’
lipophilicity-dependent lipophilic efficiency yet
Linear fit of ΔG for published data set
Mortenson & Murray (2011) JCAMD 25:663-667 DOI
Ligand efficiency, group efficiency and residuals plotted
for published data set
Some more stuff to think about
• Normalize activity using trend actually observed in
data (this means you have to model the data)
• Residuals are invariant with respect to choice in
standard concentration
• Residuals can be used with other functional forms
(e.g. non-linear and multi-linear)

More Related Content

PDF
Assessing Relative Importance using RSP Scoring to Generate VIF
PPT
Intermediate Strategies for Metabolomic Data Analysis
PPTX
Exploratory factor analysis
PPTX
Introduction to Mediation using SPSS
PDF
Multivariate data analysis regression, cluster and factor analysis on spss
PPTX
Statistical analysis in SPSS_
PPTX
Cannonical Correlation
PPTX
Factor analysis ppt
Assessing Relative Importance using RSP Scoring to Generate VIF
Intermediate Strategies for Metabolomic Data Analysis
Exploratory factor analysis
Introduction to Mediation using SPSS
Multivariate data analysis regression, cluster and factor analysis on spss
Statistical analysis in SPSS_
Cannonical Correlation
Factor analysis ppt

What's hot (18)

PPTX
Meta analysis with R
PPTX
Factor analysis
PDF
Addressing moderated mediation preacher rucker_hayes_2007
DOCX
Binary Logistic Regression
PPTX
Research Methodology (Correlational Research) By Emeral & Sarah
PPTX
Multiple Linear Regression
PPTX
PPTX
Logistic regression with SPSS examples
PPT
Statistics And Correlation
PPTX
Factor analysis
PDF
Exploratory Factor Analysis
PPT
Research Methology -Factor Analyses
PPTX
Econometrics chapter 8
PPTX
Factor Analysis for Exploratory Studies
PPT
Factor analysis
PPTX
Factor Analysis with an Example
PPTX
Path analysis
PPT
Factor analysis in Spss
Meta analysis with R
Factor analysis
Addressing moderated mediation preacher rucker_hayes_2007
Binary Logistic Regression
Research Methodology (Correlational Research) By Emeral & Sarah
Multiple Linear Regression
Logistic regression with SPSS examples
Statistics And Correlation
Factor analysis
Exploratory Factor Analysis
Research Methology -Factor Analyses
Econometrics chapter 8
Factor Analysis for Exploratory Studies
Factor analysis
Factor Analysis with an Example
Path analysis
Factor analysis in Spss
Ad

Similar to Data-analytic sins in property-based molecular design (20)

PDF
Tales of correlation inflation (2013 CADD GRC)
PDF
BrazMedChem2014
PDF
Molecular design: How to and how not to?
PPTX
Ligand efficiency: nice concept shame about the metrics
PDF
Statistics.pdf
PPT
Slides sem on pls-complete
PDF
Aspects of pharmaceutical molecular design (Fidelta version)
PDF
Data analysis
PPTX
Predicating continuous variables-1.pptx
PDF
Simple & Multiple Regression Analysis
PPTX
Factor Analysis | Introduction to Factor Analysis
PPT
A presentation for Multiple linear regression.ppt
PDF
Guide for building GLMS
PDF
Deepak_DAI101_Data_Anal_lecture6 (1).pdf
PPT
Statistics
PDF
Modeling Chemical Datasets
PPTX
Measures of Dispersion
PDF
Molecular design: One step back and two paths forward
PPTX
Linear Regression 101 Lecture SlideShare.pptx
 
PDF
Kendall's ,partial correlation and scatter plot
Tales of correlation inflation (2013 CADD GRC)
BrazMedChem2014
Molecular design: How to and how not to?
Ligand efficiency: nice concept shame about the metrics
Statistics.pdf
Slides sem on pls-complete
Aspects of pharmaceutical molecular design (Fidelta version)
Data analysis
Predicating continuous variables-1.pptx
Simple & Multiple Regression Analysis
Factor Analysis | Introduction to Factor Analysis
A presentation for Multiple linear regression.ppt
Guide for building GLMS
Deepak_DAI101_Data_Anal_lecture6 (1).pdf
Statistics
Modeling Chemical Datasets
Measures of Dispersion
Molecular design: One step back and two paths forward
Linear Regression 101 Lecture SlideShare.pptx
 
Kendall's ,partial correlation and scatter plot
Ad

More from Peter Kenny (20)

PDF
LE Metrics (EuroQSAR2016)
PDF
PWK EuroQSAR
PDF
Thermodynamics for medicinal chemistry design
PDF
partition coefficients in drug discovery
PDF
Property-based molecular design: where next? (12-Jun-2015)
PDF
Aspects of pharmaceutical molecular design (Belgrade version)
PDF
IQSC Oct 2014
PDF
UCT Oct 2014
PDF
Aspects of pharmaceutical molecular design
PDF
Perspective of pharmaceutical molecular design
PDF
Some new directions for pharmaceutical molecular design
PDF
A survey of halogens (2008 EuroCUP)
PDF
Fragment screening library workshop (IQPC 2008)
PDF
Design of fragment screening libraries (IQPC 2008)
PDF
Design of compound libraries for fragment screening (Feb 2012 version)
PDF
Design of fragment screening libraries (Feb 2010 version)
PDF
Lipophilicity in the context of molecular design
PDF
From screening to molecular interactions: A short tour
PDF
An overview of drug discovery
PDF
I'm a molecule designer... get me out of here!
LE Metrics (EuroQSAR2016)
PWK EuroQSAR
Thermodynamics for medicinal chemistry design
partition coefficients in drug discovery
Property-based molecular design: where next? (12-Jun-2015)
Aspects of pharmaceutical molecular design (Belgrade version)
IQSC Oct 2014
UCT Oct 2014
Aspects of pharmaceutical molecular design
Perspective of pharmaceutical molecular design
Some new directions for pharmaceutical molecular design
A survey of halogens (2008 EuroCUP)
Fragment screening library workshop (IQPC 2008)
Design of fragment screening libraries (IQPC 2008)
Design of compound libraries for fragment screening (Feb 2012 version)
Design of fragment screening libraries (Feb 2010 version)
Lipophilicity in the context of molecular design
From screening to molecular interactions: A short tour
An overview of drug discovery
I'm a molecule designer... get me out of here!

Recently uploaded (20)

PPTX
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPTX
Uterus anatomy embryology, and clinical aspects
PPTX
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
DOCX
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
PPTX
SKIN Anatomy and physiology and associated diseases
PPTX
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
DOC
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
PPT
MENTAL HEALTH - NOTES.ppt for nursing students
PPTX
LUNG ABSCESS - respiratory medicine - ppt
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PPTX
neonatal infection(7392992y282939y5.pptx
PPTX
Neuropathic pain.ppt treatment managment
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PPTX
History and examination of abdomen, & pelvis .pptx
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
Uterus anatomy embryology, and clinical aspects
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
SKIN Anatomy and physiology and associated diseases
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
MENTAL HEALTH - NOTES.ppt for nursing students
LUNG ABSCESS - respiratory medicine - ppt
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
neonatal infection(7392992y282939y5.pptx
Neuropathic pain.ppt treatment managment
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
History and examination of abdomen, & pelvis .pptx
Medical Evidence in the Criminal Justice Delivery System in.pdf

Data-analytic sins in property-based molecular design

  • 1. Data-analytic sins in property-based molecular design Peter Kenny pwk.pub.2008@gmail.com | http://fbdd-lit.blogspot.com
  • 2. TEP = [𝐷𝑟𝑢𝑔 𝑿,𝑡 ] 𝑓𝑟𝑒𝑒 𝐾 𝑑 Target engagement potential (TEP) A basis for molecular design?
  • 3. Property-based design as search for ‘sweet spot’
  • 4. Correlation • Strong correlation implies good predictivity – I have observed a correlation so you must use my rule • Multivariate data analysis (e.g. PCA) usually involves transformation to orthogonal basis • Applying cutoffs (e.g. MW restriction) to data can distort correlations • Noise and range limits in data
  • 5. Quantifying strengths of relationships between continuous variables • Correlation measures – Pearson product-moment correlation coefficient (R) – Spearman's rank correlation coefficient () – Kendall rank correlation coefficient (τ) • Quality of fit measures – Coefficient of determination (R2) is the fraction of the variance in Y that is explained by model – Root mean square error (RMSE)
  • 6. Preparation of synthetic data sets Kenny & Montanari (2013) JCAMD 27:1-13 DOI Add Gaussian noise (SD=10) to Y
  • 7. Correlation inflation by hiding variation See Hopkins, Mason & Overington (2006) Curr Opin Struct Biol 16:127-136 DOI Leeson & Springthorpe (2007) NRDD 6:881-890 DOI Data is naturally binned (X is an integer) and mean value of Y is calculated for each value of X. In some studies, averaged data is only presented graphically and it is left to the reader to judge the strength of the correlation. R = 0.34 R = 0.30 R = 0.31 R = 0.67 R = 0.93 R = 0.996
  • 8. r N 1202 R 0.247 ( 95% CI: 0.193 | 0.299)  0.215 ( P < 0.0001)  0.148 ( P < 0.0001) N 8 R 0.972 ( 95% CI: 0.846 | 0.995)  0.970 ( P < 0.0001)  0.909 ( P = 0.0018) Correlation Inflation in Flatland See Lovering, Bikker & Humblet (2009) JMC 52:6752-6756 DOI
  • 9. Masking variation with standard error See Gleeson (2008) JMC 51:817-834 DOI Partition by value of X into 4 bins with equal numbers of data points and display 95% confidence interval for mean (green) and mean ± SD (blue) for each bin. R = 0.12 R = 0.29 R = 0.28
  • 10. N Bins Degrees of Freedom F P 40 4 3 0.2596 0.8540 400 4 3 12.855 < 0.0001 4000 4 3 115.35 < 0.0001 4000 2 1 270.91 < 0.0001 4000 8 7 50.075 < 0.0001 “In each plot provided, the width of the errors bars and the difference in the mean values of the different categories are indicative of the strength of the relationship between the parameters.” Gleeson (2008) JMC 51:817-834 DOI The error of standard error ANOVA for binned data sets
  • 11. Know your data • Assays are typically run in replicate making it possible to estimate assay variance • Every assay has a finite dynamic range and it may not always be obvious what this is for a particular assay • Dynamic range may have been sacrificed for thoughput but this, by itself, does not make the assay bad • We need to be able analyse in-range and out-of- range data within single unified framework – See Lind (2010) QSAR analysis involving assay results which are only known to be greater than, or less than some cut-off limit. Mol Inf 29:845-852 DOI
  • 12. Depicting variation with percentile plots This graphical representation of data makes it easy to visualize variation and can be used with mixed in-range and out-of-range data. See Colclough et al (2008) BMCL 16:6611-6616 DOI
  • 13. Binning continuous data restricts your options for analysis and places burden of proof on you to show that your conclusions are independent of the binning scheme. Think before you bin! Averaging the binned data was your idea so don’t try blaming me this time!
  • 14. Correlation inflation: some stuff to think about • Model continuous data as continuous data – RMSE is most relevant to prediction but you still need R2 – Fitted parameters may provide insight (e.g. solubility is more sensitive than potency to lipophilicity) • When selecting training data think in terms of Design of Experiments (e.g. evenly spaced values of X) • Try to achieve normally distributed Y (e.g. use pIC50 rather than IC50) • Never make statements about the strength of a relationship when you’ve hidden or masked variation in the data (unless you want a starring role in Correlation Inflation 2) • To be meaningful, a measure of the spread of a distribution must be independent of sample size • Reviewers/editors, mercilessly purge manuscripts of statements like, “A negative correlation was observed between X and Y” or “A and B are correlated/linked”
  • 15. Ligand efficiency metrics (LEMs) considered harmful • We use LEMs to normalize activity with respect to risk factors such as molecular size and lipophilicity • What do we mean by normalization? • We make assumptions about underlying relationship between activity and risk factor(s) when we define an LEM • LEM as measure of extent to which activity beats a trend? Kenny, Leitão & Montanari (2014) JCAMD 28:699-710 DOI
  • 16. Scale activity/affinity by risk factor LE = ΔG/HA Offset activity/affinity by risk factor LipE = pIC50  ClogP Ligand efficiency metrics No reason that dependence of activity on risk factor should be restricted to one of these two linear models
  • 17. Use trend actually observed in data for normalization rather than some arbitrarily assumed trend
  • 18. There’s a reason why we say standard free energy of binding… DG = DH TDS = RTln(Kd/C0) • Adoption of 1 M as standard concentration is arbitrary • A view of a chemical system that changes with the choice of standard concentration is thermodynamically invalid
  • 19. NHA Kd/M C/M (1/NHA) log10(Kd/C) 10 10-3 1 0.30 20 10-6 1 0.30 30 10-9 1 0.30 10 10-3 0.1 0.20 20 10-6 0.1 0.25 30 10-9 0.1 0.27 10 10-3 10 0.40 20 10-6 10 0.35 30 10-9 10 0.33 Effect on LE of changing standard concentration
  • 20. Scaling transformation of parallel lines by dividing Y by X (This is how ligand efficiency is calculated) Size dependency of LE is consequence of non-zero intercept
  • 21. Affinity plotted against molecular weight for minimal binding elements against various targets in inhibitor deconstruction study showing variation in intercept term Hajduk PJ (2006) J Med Chem 49:6972–6976 DOI Is it valid to combine results from different assays in LE analysis?
  • 22. Offsetting transformation of lines with different slope and common intercept by subtracting X from Y (This is how lipophilic efficiency is calculated) Thankfully (hopefully?) nobody has ‘discovered’ lipophilicity-dependent lipophilic efficiency yet
  • 23. Linear fit of ΔG for published data set Mortenson & Murray (2011) JCAMD 25:663-667 DOI
  • 24. Ligand efficiency, group efficiency and residuals plotted for published data set
  • 25. Some more stuff to think about • Normalize activity using trend actually observed in data (this means you have to model the data) • Residuals are invariant with respect to choice in standard concentration • Residuals can be used with other functional forms (e.g. non-linear and multi-linear)